Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
  • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
  • A61K35/14—Blood; Artificial blood
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system

Definitions

• the invention relates to a method for producing a therapeutically active substance, particularly for healing or for treatment in geriatrics, in which defined blood from warm-blooded mammals, in particular from young cattle or calves, undergoes enzymatic hydrolysis with papain subjected, filtered, the permeate concentrated and treated with alcohol, preferably ethanol.
• Preparations usually consist of defibrinated, often also hemolyzed, blood from usually young slaughter animals, especially calves, young cattle or horses, in the usual way to free cell substances, minerals and / or protein and to concentrate the extracts as a whole or fractions thereof and to formulate as active ingredient preparations.
• deproteinization or deproteinization takes place by heating or centrifuging or filtering, or else by the action of acids or alcohols and subsequent centrifugation and / or filtration of the precipitated proteins.
• a deproteinization by heating and subsequent filtration with the aid of a membrane separation process is described in EP-A 95 170, the continuous membrane multi-stage ultrafiltration using membranes with a molecular exclusion limit of more than about 8000 daltons being used as part of the membrane separation process - Wise separation of the inorganic salts is carried out by electrodialysis with membranes with a permeability of up to about 300 daltons.
• EP-A 140 134 describes a similar process for the production of a biologically active extract from organs of mammals and from cell cultures, in which the starting material is comminuted with digestion of the cells, rapidly heated to a temperature of 70 to 90 °, cooled, centrifuged, from the solution obtained by ultrafiltration, the substances with a molecular weight of more than 10,000 D are removed and the remaining solution is removed by electrodialysis, the salt ions.
• Thymus, spleen, liver and other organs, as well as, are examples of the starting material for this * method
• High-voltage electrophoresis, high-voltage dialysis, gel filtration, thin-layer chromatography or counter-current distribution can be separated into fractions, of which those with a UV maximum at 245 to 246 m ⁇ are used to isolate the active substance.
• N of ## ## N of ##tren ⁇ ung made concentration or drying can occur for example by ultrafiltration or by spray drying.
• Organs or body fluids from mammals are obtained in order
• 25 r Glykosphi ⁇ golipide is of the following formula:
• 1-5 animals are broken down by fermentation and / or subjected to a dialysis with water or alcohols after a fractional deprotection with aliphatic alcohols or acids to remove the higher molecular weight components. If necessary, the dialysate is freed from the organic solvents and gently concentrated.
• DE-OS 2 349 186 proposes to add a physiologically usable acid addition salt of heptaminol- (6-amino-2-methylheptan-2-ol) to the preparation obtained according to DE-PS 1 076 888 above to potentiate the effect of the preparation.
• the object of the invention is to avoid these disadvantages of the known methods, to eliminate the tendency to turbidity and to increase the yield and the effectiveness of the active ingredient with improved procedural economy.
• papain hydrolysis be carried out on u-hemolyzed blood with activated papain at a pH of 6.5 to 7.4, that the reaction is then stopped by cooling, that up to 10,000 D for deproteinization and removal of papain is ultrafiltered, and then the essentially protein-free permeate is concentrated to 1/25 to 1/35, based on the blood used, and left to cool for at least 24 hours, mixed with alcohol, and ⁇ is finally filtered off.
• the simplified process procedure is also advantageous since a hemolysis step is saved. This is to be understood in this way that in the course of the enzymatic hydrolysis with papain
• I-CD hemolysis takes place, so that the two steps of hydrolysis and hemolysis take place in one.
• a later addition of water to facilitate ultrafiltration or to thermally stop the reaction no longer results in significant hemolysis.
• C5 known preparations has an increased wound healing effect.
• a comparatively improved oxygen utilization is achieved.
• cerebral blood flow and peripheral arterial blood flow are increased in comparison to known preparations.
• the method according to the invention provides surprisingly high
• ZLX booties based on the amount of blood used and is extremely economical in terms of process technology.
• Another important advantage of the method according to the invention is that it is possible to standardize the clear-filtered mixture to the desired concentration, preferably by
• defibrinated blood from slaughter animals in particular from calves or young cattle (Ms maximum 3 years) is preferably used as the starting material.
• This blood is pre-digested with an activated papain solution. Hiebei becomes a preparatory
• 3S Papai ⁇ get into the final active ingredient concentrate, the aqueous suspension is ultrafiltered. The concentrate is then mixed with cysteine solution, which activates the papain and uses it as an incubation solution. is applied.
• the blood which may have been stored in frozen form and in this case is thawed beforehand, is heated to 35-42 ° C in the incubation kettle, the pH is adjusted to 6.5-7.4 with 1N HC1 and preferably approximately with the incubation solution Incubated for 14 to 18 h.
• the completely incubated blood is mixed with fresh aqua dest.ad inject at a temperature of 0-10 ° C., whereby the enzymatic hydrolysis or pre-digestion is interrupted and the mass is diluted for the ultrafiltration.
• the ultrafilter is usually prefiltered to protect it, in order to separate particles with a size of - 50 ⁇ m.
• the - filtered concentrate is then mixed with about 2 1/2 times the volume of pre-cooled 96% ethanol and left in the cold, preferably at: cold room temperature (4-6 ° C). Instead of ethanol, methanol, propanol or butanol can also be used. After a standing time of at least 24 h, preferably about 48 h, X is filtered clear, which can be done with the help of a black band filter. The alcohol added for the precipitation is then distilled off in a Rotavapor. This usually leads to precipitation again, which is clear-filtered using black tape and glass fiber pre-filters.
• SCI * at 50 ° C or by storing the solution in the refrigerator at 5 ° C can be reduced to a few days. If the ultrafiltration is only carried out after the alcohol precipitation, the positive effect on the shelf life can no longer be determined without clouding the active ingredient, despite the concentration mentioned above.
• Comparative Product I A commercially available, protein and pyrogen-free product which is obtained from the blood of calves ready for slaughter.
• Comparative Product II Another, commercially available product, 15 produced essentially by the process according to DE-PS 1076888.
• Comparative Product III A product produced by the process according to DE-OS 1949 195. Method: Z ⁇ column: TSK 2000 SW , 0.75 x 60 cm.
• FIG. 1 The results are shown in FIG. 1 in comparison to the measurement results of the product (IV) according to the invention.
• the diagrams show the full absorption AFS (absorptio ⁇ fill scale) as a function of the retention time RT.
• the comparative products I and II each show only a single main maximum with a retention time of 47.8 and 48.2 minutes, respectively. This corresponds to an approximate molecular weight of 350-400. 1 * same product I has one shoulder each with a retention time of
• the preparation (IV) according to the invention differs significantly from UCC from the substances mentioned hitherto. It has three distinct maxi a, the first maximum being in a lower molecular weight range than in the previously mentioned preparations, namely approximately at MG 200. This is probably achieved by the additional ethanol precipitation. The other two maxima are 115 at MG ⁇ 150 and MG ⁇ 100. In addition, the preparation according to the invention shows no shoulders in the low-molecular range, but two in the higher-molecular range at MG 500 and MG 300.
• Comparative preparation I covering preparation II comparative preparation m preparation IV according to the invention 3.blekula__ weight of the total substances detectable in the experiment
• the product produced according to the invention was also tested in various test and examination series for its effectiveness in therapeutic terms. The exact test conditions will be given later.
• the preparation When examining the effect of the preparation on the incorporation of 3 H-thymidine in DNA from human fibroblasts and liver cells, it was found that the preparation has a significantly stronger (5 to 10-fold) effect on the growth of both fibroblasts and compared to known products of liver cells.
• the regenerating effect of the preparation produced according to the invention on human foreskin fibroblasts was examined, which were damaged by the withdrawal of fetal calf serum.
• the preparation according to the invention while increasing the DNA synthesis, clearly has a regenerating effect on damaged human fibroblast cells and that the concentration ranges and the inhibition range are similar to known products.
• human foreskin fibroblasts were mixed in the 8th 5 ' to 10th passage with variable amounts of the product according to the invention or the known comparative preparation I and the 3 H-thymidine incorporation in DNA was measured.
• they were first allowed to grow to 1/2 to 2/3 confluence and then in artificial medium without the addition of fetal calf serum. an essential medium component, incubated for 6 to 9 hours. The medium was then changed to one which contained only small amounts of fetal calf serum and increasing amounts of the preparation according to the invention and 3 H-labeled thymidine or of the comparative preparation I. 5- This approach was incubated for 12 to 24 hours and the radioactivity vity in the DNA fraction determined after appropriate processing of the cells.
• Fig. 2 of the accompanying drawing shows the results in diagram form, where the measurement curve for a product according to the invention is shown with full lines, that for the known comparative preparation I is shown with dashed lines.
• the preparation additions are indicated • in microliters, on the ordinate the radioactive count. 5
• the examination methodology corresponded to that of the fibroblast
• SEGD heights eg partial activity of damaged fibroblasts or increase in cellular, mitochondrial oxygen consumption. These cell-activating effects can, for example, be regarded as desirable in the context of wound healing. On the other hand, the activation of neoplastic cells would be undesirable. Investigations showed that, in contrast to the known comparative preparation I, the preparation according to the invention reduced oxygen. 1 - need of tumor cells (mouse ascites tumor cells) not activated.
• Comparative preparation I ampoules, commercial preparation (0.2 ml / chamber)
• the new preparation is therefore also excellently suited for the symptomatic treatment of psychopathological side effects - cerebral vascular insufficiency.
• the concentrate produced according to the invention can be processed for use in therapy according to methods known per se for injection solutions, tablets, dragees, wound ointments or gels.
• Therapeutic preparations according to the invention which can be wound healing or geriatric preparations in particular, contain a concentrate, optionally after it has been dried, which was produced by the previously described method.
• Papai pretreatment and activation Pretreatment of the papain is advisable in order to separate insoluble substances and to 1. To avoid that low molecular weight substances (MW - 10,000) from the Pa ⁇ pai ⁇ get into the active ingredient concentrate.
• papayotin from Extract-Chemie / activity: 80 U / mg
• centrifuged centrifuge: Sorvell 5 RC-3, rotor: HG-4L: 3,000 rpm. 20 min).
• Prefiltration for ultrafiltration (the solution should be free of particles> 10 ⁇ m) via: black filter or round filter 595, glass fiber pre-filter (from Sartorius), 8 ⁇ m membrane filter (from Sartorius) Ultrafiltration: device Pellicon cassette system from M- llip ⁇ re N> EG: 10,000 0- sample volume after centrifugation and prefiltration - * 0.77 1 concentrate volume: 0.38 1 flow rate: 60 ml / min
• Prefiltration particle size - 50 ⁇ m; device: Seitz plate filter 0: for 7 filter layers Seitz Supra 300.
• the concentrate is diluted at - ⁇ 60 1 with 30 1 and filtered - 5: again down to - * -> - 20 - 25 1 retentate.
• Total filtration volume 205 ⁇ - 2101. After 30, 100 and 2001 permeate, samples are taken to check the filter tightness using TCA precipitation (must be negative!).
• Concentration in the evaporator The ultrafiltrate is concentrated as quickly as possible in the evaporator at 60 - 80 ° C to 3 - 4 1 final volume under vacuum.
• the finished active ingredient concentrate is passed through a sterile filter (0.2 ⁇ m membrane filter, from Sartorius) and again through an ultrafilter (NMGG:
• This active ingredient concentrate is the basis for the production of ampoules, infusion solutions, tablets, dragées, capsules, ointments, gels etc.
• Preferred galenical forms are powders or granules which are filled into hard or soft gelatin capsules.
• the mixture is filtered to a concentration of 50 ml and then to 1 Activation of the Papai ⁇ s with Cystei ⁇ solution (300 mg Cystei ⁇ in 151 ml ad) diluted to a total of 200 ml.
• the ultrafiltrate is discarded.
• the incubated blood is stirred in 10 l of pre-cooled distilled water.
• the diluted blood is prefiltered for ultratiltration through a plate filter system for 7 filter layers and then filtered through an ultrafilter with a molecular weight limit of 10,000 daltons and immediately concentrated to 360 ml.
• the substances which have precipitated out due to the concentration are separated off by filtration through a black band filter.
• the protein-free filtrate is stirred into 900 ml of 10% pre-cooled ethanol 96% and left in the refrigerator at 7 ° C.
• the protein-free test is carried out in a rapid test with trichloroacetic acid. After standing for at least 48 hours, the precipitates are filtered off and the alcohol is removed in a Rotavapor. 15
• the product obtained in this way is diluted with sterile, pyrogen-free water to a dry substance content of 200 mg / ml and filled aseptically into sterile bottles. Analysis: pH 6.1
• Example 2 50 l of calf blood are defibrinated at the slaughterhouse by stirring. The fibri flakes are filtered off through a sieve. The blood is processed immediately as in Example 1. -.-.- A ⁇ alyse ⁇ date ⁇ : pH 6.0
• Example 10 '1 defibrinated fresh bovine blood is adjusted to pH 6.5 with HC1, incubated with 20 g of activated papain pretreated according to Example 1 at room temperature for 18 hours and then filtered undiluted ultra-5.
• the protein-free ultrafiltrate is concentrated to 300 ml in a vacuum evaporator, mixed with 0.75 l of ethanol and then stored in the refrigerator for 24 hours.
• the precipitate is separated off by centrifugation or filtration and the alcohol is evaporated off in a rotary evaporator.
• the concentrate is adjusted with sterile, pyrogen-free water at 0 '200 mg dry matter / ml and dispensed into sterile bottles.
• Example 5 The concentrate produced according to Examples 1 to 4 is injected with Aqua ad.
• Example 6 The concentrate produced according to Examples 1 to 4 is injected with Aqua ad 0. adjusted to a dry matter content of 50-70 mg / ml and lyophilized. Tablets are made by 500.0 glyophilisier. Concentrate 1,987.5 g of methyl cellulose, 12.5 g of Mg stearate 25. Are mixed and compressed to 250 mg tablets. Since the lyophilized concentrate is extremely hygroscopic, the tableting must take place under dry: room air ( ⁇ 20% relative humidity). The cores are coated with a saliva-resistant, white film by 30U g spray solution consisting of: 30: 12.0 g Eudragit E 100 for 750 g cores
• Example 7 1.25 1 of the concentrate prepared according to Examples 1 to 4 are made on 1 kg of granules consisting of 98% methyl cellulose and 2% gelatin, very long • sprayed on. The granules obtained in this way are subsequently dried at 60 ° C. in a drying cabinet with circulating air for at least 18 hours. After reaching a residual moisture of max. 0.5%, the granules are mixed with 0.5% Mg stearate and compressed to 250 mg tablets. & The tablets are coated as in Example 6.
• Example 8 For the production of a wound gel with a dry substance content of the active ingredient concentrate of 8 mg / g gel prepared according to Examples 1 to 4, 1-0 1.75.0 g methyl cellulose 4,000 cps are used

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Engineering & Computer Science (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Medicinal Chemistry (AREA)
• General Chemical & Material Sciences (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Organic Chemistry (AREA)
• Biotechnology (AREA)
• Immunology (AREA)
• Hematology (AREA)
• Biomedical Technology (AREA)
• Heart & Thoracic Surgery (AREA)
• Cell Biology (AREA)
• Developmental Biology & Embryology (AREA)
• Cardiology (AREA)
• Virology (AREA)
• Zoology (AREA)
• Epidemiology (AREA)
• Dermatology (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=3480490

Family Applications (1)

Country Status (4)

Cited By (4)

Citations (6)

Family Cites Families (3)

• 1988
  • 1988-01-13 AT AT0006188A patent/AT392003B/de not_active IP Right Cessation
• 1989
  • 1989-01-13 EP EP89901246A patent/EP0396597A1/de not_active Withdrawn
  • 1989-01-13 WO PCT/AT1989/000003 patent/WO1989006538A1/de not_active Application Discontinuation
  • 1989-01-13 JP JP1500995A patent/JPH03505200A/ja active Pending

Patent Citations (6)

Also Published As

Similar Documents

Legal Events